A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Epstein-Barr Virus Infection Clinical Trial

Official title:
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Status Active, not recruiting

Clinical Trial Summary

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults and the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to <18-year-old EBV-seronegative healthy adolescents.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05164094
Study type	Interventional
Source	ModernaTX, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 28, 2021
Completion date	June 18, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05683834` - Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons	Phase 1/Phase 2
Completed	`NCT02499302` - Mental Training for CFS Following EBV Infection in Adolescents	N/A
Terminated	`NCT01805037` - Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Phase 1/Phase 2
Active, not recruiting	`NCT04645147` - Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection	Phase 1
Active, not recruiting	`NCT05831111` - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults	Phase 1
Active, not recruiting	`NCT02135042` - Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA	Phase 2/Phase 3